23
Jun
A recent initiative has been launched in the UK to investigate reports concerning significant adverse effects linked to widely used weight loss medications, following multiple claims of pancreatic complications. This study, conducted by the Medicines and Healthcare products Regulatory Agency (MHRA) in collaboration with Genomics England, intends to determine if genetic components play a role in adverse reactions to these drugs.Injections aimed at controlling weight, such as well-known brands like Mounjaro, Ozempic, and Wegovy, are increasingly utilized as tools for addressing obesity and type 2 diabetes. However, health authorities are now looking into occurrences of both acute and chronic pancreatitis…
